Global Human Vaccines Administered Orally Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Human Vaccines Administered Orally market size was valued at US$ 1833.2 million in 2023. With growing demand in downstream market, the Human Vaccines Administered Orally is forecast to a readjusted size of US$ 2797.6 million by 2030 with a CAGR of 6.2% during review period.
The research report highlights the growth potential of the global Human Vaccines Administered Orally market. Human Vaccines Administered Orally are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Human Vaccines Administered Orally. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Human Vaccines Administered Orally market.
Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Human Vaccines Administered Orally market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Human Vaccines Administered Orally market. It may include historical data, market segmentation by Type (e.g., Rotavirus Vaccine, Cholera Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Human Vaccines Administered Orally market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Human Vaccines Administered Orally market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Human Vaccines Administered Orally industry. This include advancements in Human Vaccines Administered Orally technology, Human Vaccines Administered Orally new entrants, Human Vaccines Administered Orally new investment, and other innovations that are shaping the future of Human Vaccines Administered Orally.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Human Vaccines Administered Orally market. It includes factors influencing customer ' purchasing decisions, preferences for Human Vaccines Administered Orally product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Human Vaccines Administered Orally market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Human Vaccines Administered Orally market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Human Vaccines Administered Orally market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Human Vaccines Administered Orally industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Human Vaccines Administered Orally market.
Market Segmentation:
Human Vaccines Administered Orally market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Human Vaccines Administered Orally market?
What factors are driving Human Vaccines Administered Orally market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Vaccines Administered Orally market opportunities vary by end market size?
How does Human Vaccines Administered Orally break out type, application?
According to our LPI (LP Information) latest study, the global Human Vaccines Administered Orally market size was valued at US$ 1833.2 million in 2023. With growing demand in downstream market, the Human Vaccines Administered Orally is forecast to a readjusted size of US$ 2797.6 million by 2030 with a CAGR of 6.2% during review period.
The research report highlights the growth potential of the global Human Vaccines Administered Orally market. Human Vaccines Administered Orally are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Human Vaccines Administered Orally. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Human Vaccines Administered Orally market.
Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Human Vaccines Administered Orally market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Human Vaccines Administered Orally market. It may include historical data, market segmentation by Type (e.g., Rotavirus Vaccine, Cholera Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Human Vaccines Administered Orally market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Human Vaccines Administered Orally market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Human Vaccines Administered Orally industry. This include advancements in Human Vaccines Administered Orally technology, Human Vaccines Administered Orally new entrants, Human Vaccines Administered Orally new investment, and other innovations that are shaping the future of Human Vaccines Administered Orally.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Human Vaccines Administered Orally market. It includes factors influencing customer ' purchasing decisions, preferences for Human Vaccines Administered Orally product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Human Vaccines Administered Orally market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Human Vaccines Administered Orally market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Human Vaccines Administered Orally market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Human Vaccines Administered Orally industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Human Vaccines Administered Orally market.
Market Segmentation:
Human Vaccines Administered Orally market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Rotavirus Vaccine
- Cholera Vaccine
- Oral Polio Vaccine
- Public
- Private
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck
- GSK
- Sanofi
- Lanzhou Institute
- Serum Institute
- Valneva
- Shanghai United Cell
- Bibcol
- PaxVax
- Vabiotech
- Tiantan Biological
- EuBiologics
- Panacea Biotec Ltd
- Bio-Med
- Halfkin Bio-Pharmaceuticals
What is the 10-year outlook for the global Human Vaccines Administered Orally market?
What factors are driving Human Vaccines Administered Orally market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Vaccines Administered Orally market opportunities vary by end market size?
How does Human Vaccines Administered Orally break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Vaccines Administered Orally Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Human Vaccines Administered Orally by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Human Vaccines Administered Orally by Country/Region, 2019, 2023 & 2030
2.2 Human Vaccines Administered Orally Segment by Type
2.2.1 Rotavirus Vaccine
2.2.2 Cholera Vaccine
2.2.3 Oral Polio Vaccine
2.3 Human Vaccines Administered Orally Sales by Type
2.3.1 Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
2.3.2 Global Human Vaccines Administered Orally Revenue and Market Share by Type (2019-2024)
2.3.3 Global Human Vaccines Administered Orally Sale Price by Type (2019-2024)
2.4 Human Vaccines Administered Orally Segment by Application
2.4.1 Public
2.4.2 Private
2.5 Human Vaccines Administered Orally Sales by Application
2.5.1 Global Human Vaccines Administered Orally Sale Market Share by Application (2019-2024)
2.5.2 Global Human Vaccines Administered Orally Revenue and Market Share by Application (2019-2024)
2.5.3 Global Human Vaccines Administered Orally Sale Price by Application (2019-2024)
3 GLOBAL HUMAN VACCINES ADMINISTERED ORALLY BY COMPANY
3.1 Global Human Vaccines Administered Orally Breakdown Data by Company
3.1.1 Global Human Vaccines Administered Orally Annual Sales by Company (2019-2024)
3.1.2 Global Human Vaccines Administered Orally Sales Market Share by Company (2019-2024)
3.2 Global Human Vaccines Administered Orally Annual Revenue by Company (2019-2024)
3.2.1 Global Human Vaccines Administered Orally Revenue by Company (2019-2024)
3.2.2 Global Human Vaccines Administered Orally Revenue Market Share by Company (2019-2024)
3.3 Global Human Vaccines Administered Orally Sale Price by Company
3.4 Key Manufacturers Human Vaccines Administered Orally Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Vaccines Administered Orally Product Location Distribution
3.4.2 Players Human Vaccines Administered Orally Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR HUMAN VACCINES ADMINISTERED ORALLY BY GEOGRAPHIC REGION
4.1 World Historic Human Vaccines Administered Orally Market Size by Geographic Region (2019-2024)
4.1.1 Global Human Vaccines Administered Orally Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Human Vaccines Administered Orally Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Human Vaccines Administered Orally Market Size by Country/Region (2019-2024)
4.2.1 Global Human Vaccines Administered Orally Annual Sales by Country/Region (2019-2024)
4.2.2 Global Human Vaccines Administered Orally Annual Revenue by Country/Region (2019-2024)
4.3 Americas Human Vaccines Administered Orally Sales Growth
4.4 APAC Human Vaccines Administered Orally Sales Growth
4.5 Europe Human Vaccines Administered Orally Sales Growth
4.6 Middle East & Africa Human Vaccines Administered Orally Sales Growth
5 AMERICAS
5.1 Americas Human Vaccines Administered Orally Sales by Country
5.1.1 Americas Human Vaccines Administered Orally Sales by Country (2019-2024)
5.1.2 Americas Human Vaccines Administered Orally Revenue by Country (2019-2024)
5.2 Americas Human Vaccines Administered Orally Sales by Type
5.3 Americas Human Vaccines Administered Orally Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Vaccines Administered Orally Sales by Region
6.1.1 APAC Human Vaccines Administered Orally Sales by Region (2019-2024)
6.1.2 APAC Human Vaccines Administered Orally Revenue by Region (2019-2024)
6.2 APAC Human Vaccines Administered Orally Sales by Type
6.3 APAC Human Vaccines Administered Orally Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Vaccines Administered Orally by Country
7.1.1 Europe Human Vaccines Administered Orally Sales by Country (2019-2024)
7.1.2 Europe Human Vaccines Administered Orally Revenue by Country (2019-2024)
7.2 Europe Human Vaccines Administered Orally Sales by Type
7.3 Europe Human Vaccines Administered Orally Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Vaccines Administered Orally by Country
8.1.1 Middle East & Africa Human Vaccines Administered Orally Sales by Country (2019-2024)
8.1.2 Middle East & Africa Human Vaccines Administered Orally Revenue by Country (2019-2024)
8.2 Middle East & Africa Human Vaccines Administered Orally Sales by Type
8.3 Middle East & Africa Human Vaccines Administered Orally Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Vaccines Administered Orally
10.3 Manufacturing Process Analysis of Human Vaccines Administered Orally
10.4 Industry Chain Structure of Human Vaccines Administered Orally
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Vaccines Administered Orally Distributors
11.3 Human Vaccines Administered Orally Customer
12 WORLD FORECAST REVIEW FOR HUMAN VACCINES ADMINISTERED ORALLY BY GEOGRAPHIC REGION
12.1 Global Human Vaccines Administered Orally Market Size Forecast by Region
12.1.1 Global Human Vaccines Administered Orally Forecast by Region (2025-2030)
12.1.2 Global Human Vaccines Administered Orally Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Vaccines Administered Orally Forecast by Type
12.7 Global Human Vaccines Administered Orally Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Human Vaccines Administered Orally Product Portfolios and Specifications
13.1.3 Merck Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Human Vaccines Administered Orally Product Portfolios and Specifications
13.2.3 GSK Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Human Vaccines Administered Orally Product Portfolios and Specifications
13.3.3 Sanofi Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Lanzhou Institute
13.4.1 Lanzhou Institute Company Information
13.4.2 Lanzhou Institute Human Vaccines Administered Orally Product Portfolios and Specifications
13.4.3 Lanzhou Institute Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Lanzhou Institute Main Business Overview
13.4.5 Lanzhou Institute Latest Developments
13.5 Serum Institute
13.5.1 Serum Institute Company Information
13.5.2 Serum Institute Human Vaccines Administered Orally Product Portfolios and Specifications
13.5.3 Serum Institute Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Serum Institute Main Business Overview
13.5.5 Serum Institute Latest Developments
13.6 Valneva
13.6.1 Valneva Company Information
13.6.2 Valneva Human Vaccines Administered Orally Product Portfolios and Specifications
13.6.3 Valneva Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Valneva Main Business Overview
13.6.5 Valneva Latest Developments
13.7 Shanghai United Cell
13.7.1 Shanghai United Cell Company Information
13.7.2 Shanghai United Cell Human Vaccines Administered Orally Product Portfolios and Specifications
13.7.3 Shanghai United Cell Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Shanghai United Cell Main Business Overview
13.7.5 Shanghai United Cell Latest Developments
13.8 Bibcol
13.8.1 Bibcol Company Information
13.8.2 Bibcol Human Vaccines Administered Orally Product Portfolios and Specifications
13.8.3 Bibcol Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Bibcol Main Business Overview
13.8.5 Bibcol Latest Developments
13.9 PaxVax
13.9.1 PaxVax Company Information
13.9.2 PaxVax Human Vaccines Administered Orally Product Portfolios and Specifications
13.9.3 PaxVax Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 PaxVax Main Business Overview
13.9.5 PaxVax Latest Developments
13.10 Vabiotech
13.10.1 Vabiotech Company Information
13.10.2 Vabiotech Human Vaccines Administered Orally Product Portfolios and Specifications
13.10.3 Vabiotech Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Vabiotech Main Business Overview
13.10.5 Vabiotech Latest Developments
13.11 Tiantan Biological
13.11.1 Tiantan Biological Company Information
13.11.2 Tiantan Biological Human Vaccines Administered Orally Product Portfolios and Specifications
13.11.3 Tiantan Biological Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Tiantan Biological Main Business Overview
13.11.5 Tiantan Biological Latest Developments
13.12 EuBiologics
13.12.1 EuBiologics Company Information
13.12.2 EuBiologics Human Vaccines Administered Orally Product Portfolios and Specifications
13.12.3 EuBiologics Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 EuBiologics Main Business Overview
13.12.5 EuBiologics Latest Developments
13.13 Panacea Biotec Ltd
13.13.1 Panacea Biotec Ltd Company Information
13.13.2 Panacea Biotec Ltd Human Vaccines Administered Orally Product Portfolios and Specifications
13.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Panacea Biotec Ltd Main Business Overview
13.13.5 Panacea Biotec Ltd Latest Developments
13.14 Bio-Med
13.14.1 Bio-Med Company Information
13.14.2 Bio-Med Human Vaccines Administered Orally Product Portfolios and Specifications
13.14.3 Bio-Med Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Bio-Med Main Business Overview
13.14.5 Bio-Med Latest Developments
13.15 Halfkin Bio-Pharmaceuticals
13.15.1 Halfkin Bio-Pharmaceuticals Company Information
13.15.2 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Portfolios and Specifications
13.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Human Vaccines Administered Orally Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Human Vaccines Administered Orally Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Rotavirus Vaccine
Table 4. Major Players of Cholera Vaccine
Table 5. Major Players of Oral Polio Vaccine
Table 6. Global Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 7. Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Table 8. Global Human Vaccines Administered Orally Revenue by Type (2019-2024) & ($ million)
Table 9. Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2024)
Table 10. Global Human Vaccines Administered Orally Sale Price by Type (2019-2024) & (US$/Unit)
Table 11. Global Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 12. Global Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Table 13. Global Human Vaccines Administered Orally Revenue by Application (2019-2024)
Table 14. Global Human Vaccines Administered Orally Revenue Market Share by Application (2019-2024)
Table 15. Global Human Vaccines Administered Orally Sale Price by Application (2019-2024) & (US$/Unit)
Table 16. Global Human Vaccines Administered Orally Sales by Company (2019-2024) & (K Units)
Table 17. Global Human Vaccines Administered Orally Sales Market Share by Company (2019-2024)
Table 18. Global Human Vaccines Administered Orally Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Human Vaccines Administered Orally Revenue Market Share by Company (2019-2024)
Table 20. Global Human Vaccines Administered Orally Sale Price by Company (2019-2024) & (US$/Unit)
Table 21. Key Manufacturers Human Vaccines Administered Orally Producing Area Distribution and Sales Area
Table 22. Players Human Vaccines Administered Orally Products Offered
Table 23. Human Vaccines Administered Orally Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Human Vaccines Administered Orally Sales by Geographic Region (2019-2024) & (K Units)
Table 27. Global Human Vaccines Administered Orally Sales Market Share Geographic Region (2019-2024)
Table 28. Global Human Vaccines Administered Orally Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Human Vaccines Administered Orally Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Human Vaccines Administered Orally Sales by Country/Region (2019-2024) & (K Units)
Table 31. Global Human Vaccines Administered Orally Sales Market Share by Country/Region (2019-2024)
Table 32. Global Human Vaccines Administered Orally Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Human Vaccines Administered Orally Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 35. Americas Human Vaccines Administered Orally Sales Market Share by Country (2019-2024)
Table 36. Americas Human Vaccines Administered Orally Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Human Vaccines Administered Orally Revenue Market Share by Country (2019-2024)
Table 38. Americas Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 39. Americas Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 40. APAC Human Vaccines Administered Orally Sales by Region (2019-2024) & (K Units)
Table 41. APAC Human Vaccines Administered Orally Sales Market Share by Region (2019-2024)
Table 42. APAC Human Vaccines Administered Orally Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Human Vaccines Administered Orally Revenue Market Share by Region (2019-2024)
Table 44. APAC Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 45. APAC Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 46. Europe Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 47. Europe Human Vaccines Administered Orally Sales Market Share by Country (2019-2024)
Table 48. Europe Human Vaccines Administered Orally Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Human Vaccines Administered Orally Revenue Market Share by Country (2019-2024)
Table 50. Europe Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 51. Europe Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Human Vaccines Administered Orally Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Human Vaccines Administered Orally Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 57. Middle East & Africa Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Human Vaccines Administered Orally
Table 59. Key Market Challenges & Risks of Human Vaccines Administered Orally
Table 60. Key Industry Trends of Human Vaccines Administered Orally
Table 61. Human Vaccines Administered Orally Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Human Vaccines Administered Orally Distributors List
Table 64. Human Vaccines Administered Orally Customer List
Table 65. Global Human Vaccines Administered Orally Sales Forecast by Region (2025-2030) & (K Units)
Table 66. Global Human Vaccines Administered Orally Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Human Vaccines Administered Orally Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Americas Human Vaccines Administered Orally Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Human Vaccines Administered Orally Sales Forecast by Region (2025-2030) & (K Units)
Table 70. APAC Human Vaccines Administered Orally Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Human Vaccines Administered Orally Sales Forecast by Country (2025-2030) & (K Units)
Table 72. Europe Human Vaccines Administered Orally Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Human Vaccines Administered Orally Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Middle East & Africa Human Vaccines Administered Orally Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Human Vaccines Administered Orally Sales Forecast by Type (2025-2030) & (K Units)
Table 76. Global Human Vaccines Administered Orally Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Human Vaccines Administered Orally Sales Forecast by Application (2025-2030) & (K Units)
Table 78. Global Human Vaccines Administered Orally Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. Merck Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 80. Merck Human Vaccines Administered Orally Product Portfolios and Specifications
Table 81. Merck Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 82. Merck Main Business
Table 83. Merck Latest Developments
Table 84. GSK Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 85. GSK Human Vaccines Administered Orally Product Portfolios and Specifications
Table 86. GSK Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. GSK Main Business
Table 88. GSK Latest Developments
Table 89. Sanofi Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 90. Sanofi Human Vaccines Administered Orally Product Portfolios and Specifications
Table 91. Sanofi Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Lanzhou Institute Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 95. Lanzhou Institute Human Vaccines Administered Orally Product Portfolios and Specifications
Table 96. Lanzhou Institute Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97. Lanzhou Institute Main Business
Table 98. Lanzhou Institute Latest Developments
Table 99. Serum Institute Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 100. Serum Institute Human Vaccines Administered Orally Product Portfolios and Specifications
Table 101. Serum Institute Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. Serum Institute Main Business
Table 103. Serum Institute Latest Developments
Table 104. Valneva Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 105. Valneva Human Vaccines Administered Orally Product Portfolios and Specifications
Table 106. Valneva Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Valneva Main Business
Table 108. Valneva Latest Developments
Table 109. Shanghai United Cell Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 110. Shanghai United Cell Human Vaccines Administered Orally Product Portfolios and Specifications
Table 111. Shanghai United Cell Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Shanghai United Cell Main Business
Table 113. Shanghai United Cell Latest Developments
Table 114. Bibcol Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 115. Bibcol Human Vaccines Administered Orally Product Portfolios and Specifications
Table 116. Bibcol Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. Bibcol Main Business
Table 118. Bibcol Latest Developments
Table 119. PaxVax Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 120. PaxVax Human Vaccines Administered Orally Product Portfolios and Specifications
Table 121. PaxVax Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. PaxVax Main Business
Table 123. PaxVax Latest Developments
Table 124. Vabiotech Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 125. Vabiotech Human Vaccines Administered Orally Product Portfolios and Specifications
Table 126. Vabiotech Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127. Vabiotech Main Business
Table 128. Vabiotech Latest Developments
Table 129. Tiantan Biological Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 130. Tiantan Biological Human Vaccines Administered Orally Product Portfolios and Specifications
Table 131. Tiantan Biological Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 132. Tiantan Biological Main Business
Table 133. Tiantan Biological Latest Developments
Table 134. EuBiologics Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 135. EuBiologics Human Vaccines Administered Orally Product Portfolios and Specifications
Table 136. EuBiologics Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 137. EuBiologics Main Business
Table 138. EuBiologics Latest Developments
Table 139. Panacea Biotec Ltd Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 140. Panacea Biotec Ltd Human Vaccines Administered Orally Product Portfolios and Specifications
Table 141. Panacea Biotec Ltd Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 142. Panacea Biotec Ltd Main Business
Table 143. Panacea Biotec Ltd Latest Developments
Table 144. Bio-Med Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 145. Bio-Med Human Vaccines Administered Orally Product Portfolios and Specifications
Table 146. Bio-Med Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 147. Bio-Med Main Business
Table 148. Bio-Med Latest Developments
Table 149. Halfkin Bio-Pharmaceuticals Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 150. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Portfolios and Specifications
Table 151. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 152. Halfkin Bio-Pharmaceuticals Main Business
Table 153. Halfkin Bio-Pharmaceuticals Latest Developments
Table 1. Human Vaccines Administered Orally Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Human Vaccines Administered Orally Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Rotavirus Vaccine
Table 4. Major Players of Cholera Vaccine
Table 5. Major Players of Oral Polio Vaccine
Table 6. Global Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 7. Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Table 8. Global Human Vaccines Administered Orally Revenue by Type (2019-2024) & ($ million)
Table 9. Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2024)
Table 10. Global Human Vaccines Administered Orally Sale Price by Type (2019-2024) & (US$/Unit)
Table 11. Global Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 12. Global Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Table 13. Global Human Vaccines Administered Orally Revenue by Application (2019-2024)
Table 14. Global Human Vaccines Administered Orally Revenue Market Share by Application (2019-2024)
Table 15. Global Human Vaccines Administered Orally Sale Price by Application (2019-2024) & (US$/Unit)
Table 16. Global Human Vaccines Administered Orally Sales by Company (2019-2024) & (K Units)
Table 17. Global Human Vaccines Administered Orally Sales Market Share by Company (2019-2024)
Table 18. Global Human Vaccines Administered Orally Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Human Vaccines Administered Orally Revenue Market Share by Company (2019-2024)
Table 20. Global Human Vaccines Administered Orally Sale Price by Company (2019-2024) & (US$/Unit)
Table 21. Key Manufacturers Human Vaccines Administered Orally Producing Area Distribution and Sales Area
Table 22. Players Human Vaccines Administered Orally Products Offered
Table 23. Human Vaccines Administered Orally Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Human Vaccines Administered Orally Sales by Geographic Region (2019-2024) & (K Units)
Table 27. Global Human Vaccines Administered Orally Sales Market Share Geographic Region (2019-2024)
Table 28. Global Human Vaccines Administered Orally Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Human Vaccines Administered Orally Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Human Vaccines Administered Orally Sales by Country/Region (2019-2024) & (K Units)
Table 31. Global Human Vaccines Administered Orally Sales Market Share by Country/Region (2019-2024)
Table 32. Global Human Vaccines Administered Orally Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Human Vaccines Administered Orally Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 35. Americas Human Vaccines Administered Orally Sales Market Share by Country (2019-2024)
Table 36. Americas Human Vaccines Administered Orally Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Human Vaccines Administered Orally Revenue Market Share by Country (2019-2024)
Table 38. Americas Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 39. Americas Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 40. APAC Human Vaccines Administered Orally Sales by Region (2019-2024) & (K Units)
Table 41. APAC Human Vaccines Administered Orally Sales Market Share by Region (2019-2024)
Table 42. APAC Human Vaccines Administered Orally Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Human Vaccines Administered Orally Revenue Market Share by Region (2019-2024)
Table 44. APAC Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 45. APAC Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 46. Europe Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 47. Europe Human Vaccines Administered Orally Sales Market Share by Country (2019-2024)
Table 48. Europe Human Vaccines Administered Orally Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Human Vaccines Administered Orally Revenue Market Share by Country (2019-2024)
Table 50. Europe Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 51. Europe Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa Human Vaccines Administered Orally Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Human Vaccines Administered Orally Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Human Vaccines Administered Orally Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Human Vaccines Administered Orally Sales by Type (2019-2024) & (K Units)
Table 57. Middle East & Africa Human Vaccines Administered Orally Sales by Application (2019-2024) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Human Vaccines Administered Orally
Table 59. Key Market Challenges & Risks of Human Vaccines Administered Orally
Table 60. Key Industry Trends of Human Vaccines Administered Orally
Table 61. Human Vaccines Administered Orally Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Human Vaccines Administered Orally Distributors List
Table 64. Human Vaccines Administered Orally Customer List
Table 65. Global Human Vaccines Administered Orally Sales Forecast by Region (2025-2030) & (K Units)
Table 66. Global Human Vaccines Administered Orally Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Human Vaccines Administered Orally Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Americas Human Vaccines Administered Orally Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Human Vaccines Administered Orally Sales Forecast by Region (2025-2030) & (K Units)
Table 70. APAC Human Vaccines Administered Orally Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Human Vaccines Administered Orally Sales Forecast by Country (2025-2030) & (K Units)
Table 72. Europe Human Vaccines Administered Orally Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Human Vaccines Administered Orally Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Middle East & Africa Human Vaccines Administered Orally Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Human Vaccines Administered Orally Sales Forecast by Type (2025-2030) & (K Units)
Table 76. Global Human Vaccines Administered Orally Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Human Vaccines Administered Orally Sales Forecast by Application (2025-2030) & (K Units)
Table 78. Global Human Vaccines Administered Orally Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. Merck Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 80. Merck Human Vaccines Administered Orally Product Portfolios and Specifications
Table 81. Merck Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 82. Merck Main Business
Table 83. Merck Latest Developments
Table 84. GSK Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 85. GSK Human Vaccines Administered Orally Product Portfolios and Specifications
Table 86. GSK Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. GSK Main Business
Table 88. GSK Latest Developments
Table 89. Sanofi Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 90. Sanofi Human Vaccines Administered Orally Product Portfolios and Specifications
Table 91. Sanofi Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. Sanofi Main Business
Table 93. Sanofi Latest Developments
Table 94. Lanzhou Institute Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 95. Lanzhou Institute Human Vaccines Administered Orally Product Portfolios and Specifications
Table 96. Lanzhou Institute Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97. Lanzhou Institute Main Business
Table 98. Lanzhou Institute Latest Developments
Table 99. Serum Institute Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 100. Serum Institute Human Vaccines Administered Orally Product Portfolios and Specifications
Table 101. Serum Institute Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. Serum Institute Main Business
Table 103. Serum Institute Latest Developments
Table 104. Valneva Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 105. Valneva Human Vaccines Administered Orally Product Portfolios and Specifications
Table 106. Valneva Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Valneva Main Business
Table 108. Valneva Latest Developments
Table 109. Shanghai United Cell Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 110. Shanghai United Cell Human Vaccines Administered Orally Product Portfolios and Specifications
Table 111. Shanghai United Cell Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Shanghai United Cell Main Business
Table 113. Shanghai United Cell Latest Developments
Table 114. Bibcol Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 115. Bibcol Human Vaccines Administered Orally Product Portfolios and Specifications
Table 116. Bibcol Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. Bibcol Main Business
Table 118. Bibcol Latest Developments
Table 119. PaxVax Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 120. PaxVax Human Vaccines Administered Orally Product Portfolios and Specifications
Table 121. PaxVax Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. PaxVax Main Business
Table 123. PaxVax Latest Developments
Table 124. Vabiotech Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 125. Vabiotech Human Vaccines Administered Orally Product Portfolios and Specifications
Table 126. Vabiotech Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127. Vabiotech Main Business
Table 128. Vabiotech Latest Developments
Table 129. Tiantan Biological Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 130. Tiantan Biological Human Vaccines Administered Orally Product Portfolios and Specifications
Table 131. Tiantan Biological Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 132. Tiantan Biological Main Business
Table 133. Tiantan Biological Latest Developments
Table 134. EuBiologics Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 135. EuBiologics Human Vaccines Administered Orally Product Portfolios and Specifications
Table 136. EuBiologics Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 137. EuBiologics Main Business
Table 138. EuBiologics Latest Developments
Table 139. Panacea Biotec Ltd Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 140. Panacea Biotec Ltd Human Vaccines Administered Orally Product Portfolios and Specifications
Table 141. Panacea Biotec Ltd Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 142. Panacea Biotec Ltd Main Business
Table 143. Panacea Biotec Ltd Latest Developments
Table 144. Bio-Med Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 145. Bio-Med Human Vaccines Administered Orally Product Portfolios and Specifications
Table 146. Bio-Med Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 147. Bio-Med Main Business
Table 148. Bio-Med Latest Developments
Table 149. Halfkin Bio-Pharmaceuticals Basic Information, Human Vaccines Administered Orally Manufacturing Base, Sales Area and Its Competitors
Table 150. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Portfolios and Specifications
Table 151. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 152. Halfkin Bio-Pharmaceuticals Main Business
Table 153. Halfkin Bio-Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Human Vaccines Administered Orally
Figure 2. Human Vaccines Administered Orally Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Vaccines Administered Orally Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Human Vaccines Administered Orally Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Human Vaccines Administered Orally Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Rotavirus Vaccine
Figure 10. Product Picture of Cholera Vaccine
Figure 11. Product Picture of Oral Polio Vaccine
Figure 12. Global Human Vaccines Administered Orally Sales Market Share by Type in 2023
Figure 13. Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2024)
Figure 14. Human Vaccines Administered Orally Consumed in Public
Figure 15. Global Human Vaccines Administered Orally Market: Public (2019-2024) & (K Units)
Figure 16. Human Vaccines Administered Orally Consumed in Private
Figure 17. Global Human Vaccines Administered Orally Market: Private (2019-2024) & (K Units)
Figure 18. Global Human Vaccines Administered Orally Sales Market Share by Application (2023)
Figure 19. Global Human Vaccines Administered Orally Revenue Market Share by Application in 2023
Figure 20. Human Vaccines Administered Orally Sales Market by Company in 2023 (K Units)
Figure 21. Global Human Vaccines Administered Orally Sales Market Share by Company in 2023
Figure 22. Human Vaccines Administered Orally Revenue Market by Company in 2023 ($ Million)
Figure 23. Global Human Vaccines Administered Orally Revenue Market Share by Company in 2023
Figure 24. Global Human Vaccines Administered Orally Sales Market Share by Geographic Region (2019-2024)
Figure 25. Global Human Vaccines Administered Orally Revenue Market Share by Geographic Region in 2023
Figure 26. Americas Human Vaccines Administered Orally Sales 2019-2024 (K Units)
Figure 27. Americas Human Vaccines Administered Orally Revenue 2019-2024 ($ Millions)
Figure 28. APAC Human Vaccines Administered Orally Sales 2019-2024 (K Units)
Figure 29. APAC Human Vaccines Administered Orally Revenue 2019-2024 ($ Millions)
Figure 30. Europe Human Vaccines Administered Orally Sales 2019-2024 (K Units)
Figure 31. Europe Human Vaccines Administered Orally Revenue 2019-2024 ($ Millions)
Figure 32. Middle East & Africa Human Vaccines Administered Orally Sales 2019-2024 (K Units)
Figure 33. Middle East & Africa Human Vaccines Administered Orally Revenue 2019-2024 ($ Millions)
Figure 34. Americas Human Vaccines Administered Orally Sales Market Share by Country in 2023
Figure 35. Americas Human Vaccines Administered Orally Revenue Market Share by Country in 2023
Figure 36. Americas Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Figure 37. Americas Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Figure 38. United States Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 39. Canada Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 40. Mexico Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 41. Brazil Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 42. APAC Human Vaccines Administered Orally Sales Market Share by Region in 2023
Figure 43. APAC Human Vaccines Administered Orally Revenue Market Share by Regions in 2023
Figure 44. APAC Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Figure 45. APAC Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Figure 46. China Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 47. Japan Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 48. South Korea Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 49. Southeast Asia Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 50. India Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 51. Australia Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 52. China Taiwan Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 53. Europe Human Vaccines Administered Orally Sales Market Share by Country in 2023
Figure 54. Europe Human Vaccines Administered Orally Revenue Market Share by Country in 2023
Figure 55. Europe Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Figure 56. Europe Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Figure 57. Germany Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 58. France Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 59. UK Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 60. Italy Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 61. Russia Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 62. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Country in 2023
Figure 63. Middle East & Africa Human Vaccines Administered Orally Revenue Market Share by Country in 2023
Figure 64. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Figure 65. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Figure 66. Egypt Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 67. South Africa Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 68. Israel Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 69. Turkey Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 70. GCC Country Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Human Vaccines Administered Orally in 2023
Figure 72. Manufacturing Process Analysis of Human Vaccines Administered Orally
Figure 73. Industry Chain Structure of Human Vaccines Administered Orally
Figure 74. Channels of Distribution
Figure 75. Global Human Vaccines Administered Orally Sales Market Forecast by Region (2025-2030)
Figure 76. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Region (2025-2030)
Figure 77. Global Human Vaccines Administered Orally Sales Market Share Forecast by Type (2025-2030)
Figure 78. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Type (2025-2030)
Figure 79. Global Human Vaccines Administered Orally Sales Market Share Forecast by Application (2025-2030)
Figure 80. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Human Vaccines Administered Orally
Figure 2. Human Vaccines Administered Orally Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Vaccines Administered Orally Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Human Vaccines Administered Orally Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Human Vaccines Administered Orally Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Rotavirus Vaccine
Figure 10. Product Picture of Cholera Vaccine
Figure 11. Product Picture of Oral Polio Vaccine
Figure 12. Global Human Vaccines Administered Orally Sales Market Share by Type in 2023
Figure 13. Global Human Vaccines Administered Orally Revenue Market Share by Type (2019-2024)
Figure 14. Human Vaccines Administered Orally Consumed in Public
Figure 15. Global Human Vaccines Administered Orally Market: Public (2019-2024) & (K Units)
Figure 16. Human Vaccines Administered Orally Consumed in Private
Figure 17. Global Human Vaccines Administered Orally Market: Private (2019-2024) & (K Units)
Figure 18. Global Human Vaccines Administered Orally Sales Market Share by Application (2023)
Figure 19. Global Human Vaccines Administered Orally Revenue Market Share by Application in 2023
Figure 20. Human Vaccines Administered Orally Sales Market by Company in 2023 (K Units)
Figure 21. Global Human Vaccines Administered Orally Sales Market Share by Company in 2023
Figure 22. Human Vaccines Administered Orally Revenue Market by Company in 2023 ($ Million)
Figure 23. Global Human Vaccines Administered Orally Revenue Market Share by Company in 2023
Figure 24. Global Human Vaccines Administered Orally Sales Market Share by Geographic Region (2019-2024)
Figure 25. Global Human Vaccines Administered Orally Revenue Market Share by Geographic Region in 2023
Figure 26. Americas Human Vaccines Administered Orally Sales 2019-2024 (K Units)
Figure 27. Americas Human Vaccines Administered Orally Revenue 2019-2024 ($ Millions)
Figure 28. APAC Human Vaccines Administered Orally Sales 2019-2024 (K Units)
Figure 29. APAC Human Vaccines Administered Orally Revenue 2019-2024 ($ Millions)
Figure 30. Europe Human Vaccines Administered Orally Sales 2019-2024 (K Units)
Figure 31. Europe Human Vaccines Administered Orally Revenue 2019-2024 ($ Millions)
Figure 32. Middle East & Africa Human Vaccines Administered Orally Sales 2019-2024 (K Units)
Figure 33. Middle East & Africa Human Vaccines Administered Orally Revenue 2019-2024 ($ Millions)
Figure 34. Americas Human Vaccines Administered Orally Sales Market Share by Country in 2023
Figure 35. Americas Human Vaccines Administered Orally Revenue Market Share by Country in 2023
Figure 36. Americas Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Figure 37. Americas Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Figure 38. United States Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 39. Canada Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 40. Mexico Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 41. Brazil Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 42. APAC Human Vaccines Administered Orally Sales Market Share by Region in 2023
Figure 43. APAC Human Vaccines Administered Orally Revenue Market Share by Regions in 2023
Figure 44. APAC Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Figure 45. APAC Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Figure 46. China Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 47. Japan Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 48. South Korea Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 49. Southeast Asia Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 50. India Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 51. Australia Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 52. China Taiwan Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 53. Europe Human Vaccines Administered Orally Sales Market Share by Country in 2023
Figure 54. Europe Human Vaccines Administered Orally Revenue Market Share by Country in 2023
Figure 55. Europe Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Figure 56. Europe Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Figure 57. Germany Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 58. France Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 59. UK Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 60. Italy Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 61. Russia Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 62. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Country in 2023
Figure 63. Middle East & Africa Human Vaccines Administered Orally Revenue Market Share by Country in 2023
Figure 64. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
Figure 65. Middle East & Africa Human Vaccines Administered Orally Sales Market Share by Application (2019-2024)
Figure 66. Egypt Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 67. South Africa Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 68. Israel Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 69. Turkey Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 70. GCC Country Human Vaccines Administered Orally Revenue Growth 2019-2024 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Human Vaccines Administered Orally in 2023
Figure 72. Manufacturing Process Analysis of Human Vaccines Administered Orally
Figure 73. Industry Chain Structure of Human Vaccines Administered Orally
Figure 74. Channels of Distribution
Figure 75. Global Human Vaccines Administered Orally Sales Market Forecast by Region (2025-2030)
Figure 76. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Region (2025-2030)
Figure 77. Global Human Vaccines Administered Orally Sales Market Share Forecast by Type (2025-2030)
Figure 78. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Type (2025-2030)
Figure 79. Global Human Vaccines Administered Orally Sales Market Share Forecast by Application (2025-2030)
Figure 80. Global Human Vaccines Administered Orally Revenue Market Share Forecast by Application (2025-2030)
More Publications
Global Pain Management Patch Market Growth 2024-2030
US$ 3,660.00
March 2024
95 pages
Global Medical Surgical Headlight Market Growth 2025-2031
US$ 3,660.00
April 2025
162 pages
Global COVID-19 Antibody Detection Kits Market Growth 2025-2031
US$ 3,660.00
January 2025
136 pages
Global Varicose Vein Treatment Device Market Growth 2023-2029
US$ 3,660.00
March 2023
100 pages
